MolecularMatch is a clinical informatics company with expertise in precision oncology, immunotherapy and bioinformatics, combined with clinical insights empowering your solution. Leveraging technology licensed from the world’s #1 cancer center, M.D. Anderson, MolecularMatch has created unique proprietary treatment algorithms from world-leading physicians and scientists.
MolecularMatch is uniquely positioned to integrate with existing systems, allowing us to service a variety of companies throughout the Health and Life Sciences industry. We partner with you to develop the most effective solution, based on your workflow and mission. MolecularMatch offers the technology, intellect and experience to be your trusted partner in advancing the clinical utility of genomics and realizing the promise of precision medicine.
Dr. Krenitsky brings more than 15 years of experience leading and managing global diagnostic and biotechnology operations. Through December 2014, Dr. Krenitsky was Chief Commercial Officer & SVP of International Strategy and previously Chief Operating officer at Foundation Medicine. Prior to that, he served as President of Enzo Clnical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests. Dr. Krenitsky has also served as Chief Executive Officer at both a global biotechnology company and a Clinical Diagnostic Lab. Dr. Krenitsky received his B.S. in Business Management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia. He is a former member of the Board of Directors of the New York State Clinical Lab Assocation and of BioServe Biotechnologies, and currently serves on the Board of Directors at Lumicell.
James W. Welsh, MD, specializes in the treatment of thoracic cancers at the M.D. Anderson Cancer Center. His oncology career began at Genentech Inc., working on the first targeted therapies. He later attended Dartmouth Medical School, where his laboratory work was developing AKT inhibitors to radiosensitize tumors. He completed a residency in radiation oncology at the University of Arizona, where he also ran a laboratory focused on radiosensitizers, which lead to a novel c-Met inhibitor MP470. He joined the clinical faculty at M.D. Anderson in 2008. His pursuits extend from the laboratory to the clinic, with a focus on translational research, developing novel personalized therapeutics and immunotherapies to combine with radiation.
John brings over 20 years of financial experience to MolecularMatch. With specific expertise in budgeting & modeling and raising equity he joins MolecularMatch to aid in company growth and progress.
Nick has been architecting and implementing enterprise applications for over 20 years. Grounded in collaborative development and user-centered design, Nick applies his experience in full-stack architecture. He co-developed GluJs, an open source UI framework for building enterprise-ready web and mobile applications. He holds a Bachelor's of Science degree in Electrical Engineering from Bradley University.
At MolecularMatch Xuan Shirley Li, PhD integrates her biological pathways knowledge with software applications development. Shirley's experience ranges from transcriptomic profiling and systems biology at MIT, a PhD thesis on ARID1 in epigenetics from New York University, postdoc at Oxford University on drug discovery, and gene editing in somatic mosaicism modeling for early hematopoietic differentiation.
Don has been in healthcare for nearly 30 years and oversees new business development for MolecularMatch. He boasts a comprehensive understanding of genomics, bioinformatics and integrated healthcare IT systems. Formerly at Baylor College of Medicine's Genetics Lab, he was Director of Strategic Partnerships overseeing both national and international clients.
Dr. Chang currently serves as the CEO/President of Apex Enterprises, Inc., an investment management company focused on investments in healthcare, education and socially responsible ventures. In addition to investing, Apex also participates in active operations of companies including STEAMtrax, LLC., where Dr. Chang is a member of the Board of Managers. Prior to that Dr. Nancy was the Co-Founder, President, Chief Executive Officer and Chairman of Tanox (1986-2006). Tanox focused its effort on the development of therapeutics to address major unmet medical needs in the areas of asthma, allergy, inflammation, aged macular degeneration and other diseases affecting the human immune system. Dr. Chang’s pharmaceutical development experience stemmed from her tenure at the Roche Institute of Molecular Biology from 1979-1980. Dr. Chang graduated from National Tsing Hua University in Taiwan and received her Ph. D. from Harvard University, the Division of Medical Sciences at Harvard Medical School in 1979.
In her over 30 year tenure in the biotechnology industry, she has developed and commercialized a number of highly successful diagnostic and therapeutic products. Even today, there are breakthrough drugs are coming to the market due to Dr. Chang’s work. Dr. Chang has served on the boards of a number of companies, including Charles River Laboratory International, Inc., Eddingpharm (Cayman) Inc., Crown Bioscience Inc., Applied Optoelectronics Inc., SciClone Pharmaceuticals Inc. and STEAMtrax, LLC. and many other private companies. In addition, Dr. Chang was a member of the board of directors at BIO (the Biotech Industry Organization in the U.S.) and BioHouston (the biotech industry organization in Houston, Texas) and recently Dr. Chang was elected to be on the board of Asia Society in Texas. Dr. Chang was also a Director at the Federal Reserve Bank in Dallas, Houston Branch from 2005 to 2009 and a Director for Project Hope.
Dr. Scott Kopetz graduated Summa Cum Laude from Vanderbilt University with a bachelor’s degree in Biomedical Engineering/Electrical and received his medical degree from Johns Hopkins School of Medicine. He obtained his residency training in Internal Medicine at Duke University Medical Center, followed by a medical oncology fellowship at M. D. Anderson Cancer Center. Dr. Kopetz joined M. D. Anderson Cancer Center in 2006 as an Assistant Professor of Medicine in the Department of Gastrointestinal Medical Oncology. He subsequently completed a Ph.D. at M.D. Anderson in cancer biology with thesis focus on mechanisms of chemotherapy resistance in colorectal cancer.
Dr. Kopetz is board-certified in Internal Medicine and in Medical Oncology. He has authored over 100 peer-reviewed articles in respected scientific journals such as Journal of Clinical Oncology, Lancet, Cancer Research, Cancer, Clinical Cancer Research, and JAMA, and is a senior editor for Clinical Cancer Research, and editorial board member on Journal of Clinical Oncology and JNCI. He is vice-chair for colon cancer research in the NSABP/RTOG cooperative group, and member of the NIH Gastrointestinal Oncology Steering Committee. In addition, he was a recipient of peer-reviewed grants from American Society of Clinical Oncology and the National Institute of Health, among others. He is the principal investigator several phase I and II clinical trials, including of Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study, a novel biomarker enrichment program for colorectal cancer. His research interests include the biology of the refractory colorectal cancer and the development of novel therapeutics for molecularly distinct subsets of colorectal cancer patients.
Dr. David S. Hong is an Associate Professor and Deputy Chair in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center. The approach of the department is unique with an emphasis on molecular characterization of each patient’s tumor and personalized therapy in the Phase I setting. Throughout his career, Dr. Hong has developed an interest in studying the efficacy of novel drug combinations in patients with solid tumors. As a faculty member in the Department of Investigational Cancer Therapeutics he has an extensive track record of leading successful studies that involve a strong correlative component and collaborating with other investigators both basic and clinical within MD Anderson and outside institutions. Currently, he is the Principal Investigator on twenty research protocols that involve a wide range of sponsors including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. Dr. Hong has been an author or co-author on over 150 publications. Recently his research endeavors have focused on developing personalized therapies for patients whose tumors bear specific genetic mutations/amplifications. At this time, all patients presented to the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center are being screened for mutational status through the MD Anderson Department of Pathology using CLIA certified testing. Dr. Hong has demonstrated the ability to successfully place patients on clinical trials, manage toxicities and oversee the correlative studies associated with various phase I research projects.
Dr. Kim is Chairman at the Levine Cancer Institute within the Carolinas HealthCare System. His previous experience includes tenure as an Associate Professor at MD Anderson Cancer Center. He specializes in Lung Cancer, Head and Neck Cancer, and Solid Tumor Oncology. Dr. Kim went to medical school at Northwestern University and completed his residency at Baylor College of Medicine and Fellowship at MD Anderson Cancer Center.
Dr. Mok is a professor of Clinical Oncology at the University of Hong Kong, focusing on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led multi-national studies that help establish the global standard on personalized medicine for lung cancer. He was previously the President of the International Association for the Study of Lung Cancer. Dr. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in Medical Oncology at the Princess Margaret Hospital in Canada.
The MolecularMatch team is comprised of industry professionals including biologists, clinicians and engineers who believe it is their responsibility to be leaders in providing quality and compliant information. In an industry in which data standards are lacking, we strive to deliver content of the highest data integrity. We continually collaborate with and collect recommendations from industry experts so that these insights can be shared with you.